Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginkgo Bioworks Holdings's quarterly market cap
increased
from Sep. 2025 (MXN13,470 Mil) to Dec. 2025 (MXN16,822 Mil) but then
declined
from Dec. 2025 (MXN16,822 Mil) to Mar. 2026 (MXN10,860 Mil).
Ginkgo Bioworks Holdings's annual market cap
declined
from Dec. 2023 (MXN60,020 Mil) to Dec. 2024 (MXN8,916 Mil) but then
increased
from Dec. 2024 (MXN8,916 Mil) to Dec. 2025 (MXN16,822 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ginkgo Bioworks Holdings's Enterprise Value for Today is MXN9,815 Mil.
Ginkgo Bioworks Holdings (MEX:DNA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ginkgo Bioworks Holdings Market Cap Related Terms
Ginkgo Bioworks Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:DNA vs RZLT, EIKN, ARTV: Market Cap Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ginkgo Bioworks Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (MEX:DNA) has a Market Cap of MXN9,169 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ginkgo Bioworks Holdings and its competitors. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #383 out of 1423 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Ginkgo Bioworks Holdings' Market Cap too high?
Ginkgo Bioworks Holdings' current Market Cap is MXN9,169 Mil. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #383 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Market Cap compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #383 out of 1423 companies for Market Cap. This puts Ginkgo Bioworks Holdings in the upper half of its industry. The industry median Market Cap is 112.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.87, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 112.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Market Cap is MXN9,169 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (MEX:DNA) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN149.41, compared to a current price of MXN170.00 — trading 13.8% above its estimated fair value. The current Market Cap is MXN9,169 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (MEX:DNA), the current Market Cap is MXN9,169 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (MEX:DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of MXN170.00 is trading 13.8% above its estimated GF Value™ of MXN149.41.
GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Undervalued.
Key valuation signals for MEX:DNA:
Market Cap: MXN9,169 Mil
GF Value™: MXN149.41 vs. price of MXN170.00 (13.8% above fair value)
No single metric tells the full story. See the MEX:DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
54GF Score
Get the complete analysis for MEX:DNA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DNA has been successfully added to your 
